Drugs / CVL237
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07446049 | May 2026 → Jan 2028 expected | — | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06183736 | Dec 2023 → Jun 2025 overdue | cancer | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06293716 | Mar 2024 → Dec 2025 | activated PI3K-delta syndrome | Convalife (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVL237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06183736 ↗ |
| Route | Oral | “to take an oral CVL237 tablet or a placebo CVL237 simulant once daily.” NCT06293716 ↗ |